Search the Newsreel

Cellebrite DI (CLBT) Names Shiven Ramji CEO As Revenue Guidance Is Cut

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Cellebrite DI (NasdaqGS: CLBT) announced a planned CEO transition, with Shiven Ramji set to succeed Thomas E. Hogan. Ramji joined Cellebrite DI earlier this year as President, …

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Xcel Brands Inc earnings beat by $0.14, revenue fell short of estimates

Xcel Brands Inc (NASDAQ: XELB) reported second-quarter EPS of $-0.210, surpassing analyst estimates by $0.14. However, the company's revenue of $1.1M fell short of the consensus estimate of $1.8M. InvestingPro indicates that Xcel Brands Inc currently has a "weak performance" financial health score.

Suzano Papel E Celulose Balances Pulp Strength and Costs

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript

ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS

ImmuCell (NASDAQ:ICCC) reported its earnings results, beating the consensus estimate by $0.15 EPS with reported earnings of $0.20 per share. The biotechnology company also surpassed revenue expectations, bringing in $7.19 million against an anticipated $5.40 million. Despite these positive financial results, the company maintains …

Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan Sells 139,713 Shares of Stock

Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan sold 139,713 shares of the company's stock for approximately $2.15 million, reducing his direct ownership by 15.02%. The sale comes as Cellebrite's stock fell, trading below its moving averages, and the company recently lowered its 2026 revenue and …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

Cellebrite DI Ltd (CLBT) (Q2 2026) Earnings Call Highlights: ARR Misses Guidance, Full-Year ...

This article first appeared on GuruFocus. ARR: Increased 21% to $508 million, missing the bottom end of guidance. Revenue: $131 million, up 16% year-over-year. Subscription Revenue: $119.5 million, up 16%, representing 91% of total revenue. Gross Profit: Increased 16% to $112 million, with a …

Celcuity Q2 Earnings Call Highlights

Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …

CELCUITY ($CELC) Releases Q2 2026 Earnings

XCel Brands (XELB) Reports Q2 Loss, Lags Revenue Estimates

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) reported a Q2 loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.51 loss, but missed revenue estimates with $0.18 million, 46.47% below consensus. Despite an earnings surprise this quarter and last, the company's shares have fallen 33.8% …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

Stock Market Today, Aug. 13: Cellebrite Shares Plummet 29% After Missing Earnings, Cutting 2026 Revenue Guidance

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Xcel Brands (XELB) Q2 2026 loss deepens liquidity concerns despite asset sale

Xcel Brands (XELB) reported a Q2 2026 net loss of $2.48 million, highlighting significant liquidity risks despite actions like selling the Judith Ripka brand for $2.30 million cash and refinancing part of its term loan. The company's net licensing revenue decreased, and management expressed …

XCel Brands: Q2 Earnings Snapshot

Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake

Bleichroeder entities, led by Bleichroeder LP and Andrew Gundlach, have reported a 9.99% equity stake in Cellectar Biosciences (CLRB), amounting to 808,300 common shares. Bleichroeder LP, a registered investment adviser, holds these shares for various advisory clients, granting them sole voting and dispositive power …

BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12

Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …

IMMUCELL CORP /DE/ Q2 2026: Revenue $7.19M, EPS $0.2— 10-Q Summary

IMMUCELL CORP /DE/ (ICCC) reported strong second-quarter 2026 results, with revenue reaching $7.19M and diluted EPS of $0.20, significantly up from the previous year. This growth was primarily driven by increased volumes and pricing for its First Defense product, which accounted for over 99% …

ImmuCell Plans About $4.5M Expansion for Calf Health Products

ImmuCell (NASDAQ: ICCC) reported strong Q2 2026 financial results with product sales up 11.5% to $7.2 million and net income rising to $1.8 million, aided by a $2 million legal settlement. The company announced a two-phase, approximately $8.0 million expansion of its First Defense® …

ImmuCell Corporation (ICCC) doubles profit on higher First Defense sales

ImmuCell Corporation reported robust financial results for the first half of 2026, with net income doubling to $3.8 million due to increased First Defense sales and a significant $2.0 million settlement. The company's product sales grew by 20.9% to $17.5 million, largely driven by …

FuelCell Energy (NASDAQ:FCEL) Shares Down 7.1% - Here's What Happened

FuelCell Energy (NASDAQ:FCEL) shares dropped 7.1% on Thursday, closing at $20.13, with trading volume below average. The company reported a significant quarterly loss and lower-than-expected revenue. Analyst sentiment is mixed, resulting in a consensus "Hold" rating and an average price target of $22.83.

Energy company locks Colorado mom’s thermostat during scorching heat wave — ‘not safe’

A Colorado woman, Kyri Baker, found her thermostat locked by Xcel Energy during a heatwave, preventing her from lowering her home's temperature below 79 degrees. This occurred despite her voluntary enrollment in Xcel's Saver's Switch program, which offers a $40 monthly credit for allowing …

Xcel Brands Revenue Falls 14% as Q2 Net Loss Narrows

Cellebrite (CLBT) boosts H1 2026 revenue 17% while net income falls sharply

Accelerant Holdings Class A Common Shares (NYSE:ARX) Stock Quote

This article provides a stock quote and recent news for Accelerant Holdings Class A Common Shares (NYSE:ARX). It highlights the company's current stock price, trading volume, performance metrics, and a series of news headlines, including a recent surge due to a $4 billion all-cash …

Turkcell Iletisim Hizmetleri AS (NYSE:TKC) Issues Quarterly Earnings Results

Bolstered by PepsiCo Partnership, Celsius' Growth Outlook Looks Strong Despite Near-Term Volatility

Celsius Holdings' growth outlook remains strong due to its long-term partnership with PepsiCo and the acquisition of Alani Nu, which helps tap into female consumer demand. Despite these positives, Morningstar analysts express skepticism about Celsius establishing a durable competitive position given the intense competition …

Shareholder Alert: Ademi LLP investigates whether Accelerant Holdings is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Accelerant Holdings (NYSE: ARX) for potential breaches of fiduciary duty related to its recently announced transaction with Thoma Bravo. The firm is concerned about whether public shareholders are receiving a fair price of $20.25 per share, especially given the substantial …

Cellebrite Q2: This 33% Selloff Looks Like An Overreaction (NASDAQ:CLBT)

Cellebrite DI Ltd. (CLBT) experienced a significant 33% stock drop post-earnings, which the author believes is an overreaction. Despite missing Q2 guidance for ARR and revenue growth, and facing management transition and slower Inseyets conversions, the company maintains strong core products, high retention, and …